Mellisa Hall
Nurse Practitioner · Princeton, INNPI 1831191030
Payments from drug & device makers
Across 88 payments — averaging $16.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$323
- AbbVie$233
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$152
- Lundbeck LLC$107
- Takeda Pharmaceuticals U.S.A., Inc.$72
- Amgen$71
- plus $527 from 17 others
What the payments were for
- Food & beverage$1,485100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$1,485 in reported general payments places this provider in the 75th percentile of 2,724 nurse practitioner providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 70 | $50,208 |
| TrulicityDulaglutide | 30 | $31,688 |
| JardianceEmpagliflozin | 22 | $25,725 |
| XareltoRivaroxaban | 14 | $18,727 |
| VraylarCariprazine Hcl | 11 | $17,480 |
| OzempicSemaglutide | 17 | $16,222 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $15,824 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 13 | $8,299 |
| Spiriva RespimatTiotropium Bromide | 15 | $7,785 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $6,003 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $4,486 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 21 | $3,015 |
| Verapamil Er PmVerapamil Hcl | 14 | $2,261 |
| Aripiprazole | 18 | $1,757 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 121 | $1,706 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat | $29 | $33,51137 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $34 | $21,82629 claims |
| AbbVieVraylar | $233 | $17,48011 claims |
| Novo NordiskOzempic | $60 | $16,22217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,724 nurse practitioner providers in Indiana.
Other nurse practitioner in Princeton
- Kristi OrbaughIndianapolis$1.3M
- Kimberly EadsPlainfield$302K
- Sean GoddardFort Wayne$180K
- Kacy RogersIndianapolis$77K
- Kristine TaylorFort Wayne$69K
- Brittany SavageIndianapolis$51K
- Monica HaugerTrafalgar$47K
- Rhonda HettingerClarksville$38K
- Jennifer MaahsIndianapolis$36K
- Amber MillerLawrenceburg$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.